Advocacy

Patient Safety: Biologics and Biosimilars

Since about 2015 the issue on biologics and biosimilars has received a lot of attention from the medical, regulatory and patient community. Licensing rights of biological medicines used in the treatment not only of IBD but also other autoimmune modulated diseases are coming to an end and biosimilars medicines are being developed to compete with original biological treatment options. In various countries in the EU and elsewhere biosimilars have already entered the market.  

Read time: 4 mins

Patient and physician perspectives on managing iron deficiency with or without anaemia in inflammatory bowel disease

P328 Patient and physician perspectives on managing iron deficiency with or without anaemia in inflammatory bowel disease: findings from a European online survey 

January, 2017

Iron deficiency (ID) and iron deficiency anaemia (IDA) are conditions frequently observed in patients with inflammatory bowel disease (IBD) and require appropriate treatment. This study investigated patient and physician perspectives on the management of these conditions.

Read time: 1 min

Patient Perspectives on Biosimilars

Patient Perspectives on Biosimilars: A Survey by the European Federation of Crohn's and Ulcerative Colitis

July, 2016

The aim of this survey was to find out the patients' perspectives concerning biosimilars. An online survey consisting of 14 questions was made available between November 2014 and October 2015. Only respondents who had heard of biosimilars were asked to respond the final twelve questions.

Read study

Read time: 1 min

World Symposium on IBD research funded by IBD patient associations

World Symposium on IBD Research funded by IBD patients associations

Global alliance against IBD

On 18 October 2012,  the European Federation of Crohn's & Ulcerative Colitis Associations (EFCCA) met  in Brussels with worldwide patient associations for the first ever World Symposium on IBD research funded or promoted by IBD patients' associations.

Read time: 2 mins

A European Crohn's and ulcerative colitis patient life IMPACT survey

P406 A European Crohn's and ulcerative colitis patient life IMPACT survey

February, 2012

Inflammatory bowel diseases (IBD) significantly impact the lives of patients. The European Federation of ulcerative Colitis and Crohn’s Associations (EFCCA) undertook a pan-European patient survey assessing the perspectives of IBD patients about their disease and its impact on their lives, relationships and careers. The project has been supported by an unrestricted educational grant from Abbott.

Read time: 1 min